DK0787726T3 - Ny forbindelse, fremgangsmåde til fremstilling deraf og antitumor-middel - Google Patents

Ny forbindelse, fremgangsmåde til fremstilling deraf og antitumor-middel

Info

Publication number
DK0787726T3
DK0787726T3 DK95920265T DK95920265T DK0787726T3 DK 0787726 T3 DK0787726 T3 DK 0787726T3 DK 95920265 T DK95920265 T DK 95920265T DK 95920265 T DK95920265 T DK 95920265T DK 0787726 T3 DK0787726 T3 DK 0787726T3
Authority
DK
Denmark
Prior art keywords
hydrogen atom
preparation
group
lower alkyl
alkyl group
Prior art date
Application number
DK95920265T
Other languages
Danish (da)
English (en)
Inventor
Kyoji Tomita
Katsumi Chiba
Shigeki Kashimoto
Koh-Ichiro Shibamori
Yasunori Tsuzuki
Original Assignee
Dainippon Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dainippon Pharmaceutical Co filed Critical Dainippon Pharmaceutical Co
Application granted granted Critical
Publication of DK0787726T3 publication Critical patent/DK0787726T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DK95920265T 1994-06-14 1995-06-06 Ny forbindelse, fremgangsmåde til fremstilling deraf og antitumor-middel DK0787726T3 (da)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
JP15657894 1994-06-14
JP19792194 1994-07-28
JP30691494 1994-11-15
JP33995694 1994-12-28
JP8170595 1995-03-13
PCT/JP1995/001110 WO1995034559A1 (en) 1994-06-14 1995-06-06 Novel compound, process for producing the same, and antitumor agent

Publications (1)

Publication Number Publication Date
DK0787726T3 true DK0787726T3 (da) 2002-02-11

Family

ID=27524935

Family Applications (1)

Application Number Title Priority Date Filing Date
DK95920265T DK0787726T3 (da) 1994-06-14 1995-06-06 Ny forbindelse, fremgangsmåde til fremstilling deraf og antitumor-middel

Country Status (27)

Country Link
US (1) US5817669A (enExample)
EP (1) EP0787726B1 (enExample)
JP (1) JP3391796B2 (enExample)
KR (1) KR100350921B1 (enExample)
CN (1) CN1053668C (enExample)
AT (1) ATE209645T1 (enExample)
AU (1) AU679859B2 (enExample)
BR (1) BR9508037A (enExample)
CA (1) CA2192824C (enExample)
CZ (1) CZ292631B6 (enExample)
DE (1) DE69524251T2 (enExample)
DK (1) DK0787726T3 (enExample)
ES (1) ES2163512T3 (enExample)
FI (1) FI112485B (enExample)
HK (1) HK1000495A1 (enExample)
HU (1) HU220072B (enExample)
MX (1) MX9606331A (enExample)
NO (1) NO307255B1 (enExample)
NZ (1) NZ287139A (enExample)
PL (1) PL181867B1 (enExample)
PT (1) PT787726E (enExample)
RO (1) RO117793B1 (enExample)
RU (1) RU2151770C1 (enExample)
SI (1) SI0787726T1 (enExample)
SK (1) SK281341B6 (enExample)
TW (1) TW319769B (enExample)
WO (1) WO1995034559A1 (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20040309A2 (en) * 2001-09-26 2006-05-31 Bayer Pharmaceuticals Corporation 1,6-nafthyridine derivatives as antidiabetics
US6802423B2 (en) * 2002-02-20 2004-10-12 Trans Global Foods, Inc. Disposable food delivery apparatus
EP1610795A4 (en) * 2003-04-07 2007-10-24 Cylene Pharmaceuticals Inc SUBSTITUTED 1,4-DIHYDRO-4-OXO-1,8-NAPHTHPYRIDINE HETEROCYCLIC ANALOGUES
ES2424676T3 (es) * 2003-09-10 2013-10-07 Kyorin Pharmaceutical Co., Ltd. Derivado de ácido 7-(3-ciclopropilaminometil-1-pirrolidinil 4-sustituido)quinoloncarboxílico
DE10352979A1 (de) * 2003-11-13 2005-06-09 Merck Patent Gmbh Pyridopyrimidinone
CN101703508A (zh) * 2004-03-15 2010-05-12 逊尼希思制药公司 Sns-595及其使用方法
AU2013201203C1 (en) * 2004-03-15 2015-04-23 Sumitomo Dainippon Pharma Co., Ltd. Sns-595 and methods of using the same
MX2007004274A (es) * 2004-10-14 2007-05-16 Hoffmann La Roche Quinazolinilmetilentiazolinonas como inhibidores de cdk1.
BRPI0516488A (pt) * 2004-10-14 2008-09-09 Hoffmann La Roche azolidinonas de 1,5-naftiridina tendo atividade antiproliferativa de cdk1
RU2420524C2 (ru) * 2005-05-19 2011-06-10 Дайити Санкио Компани, Лимитед Производные три- или тетра-замещенного-3-аминопирролидина
US7563805B2 (en) * 2005-05-19 2009-07-21 Daiichi Pharmaceutical Co., Ltd. Tri-, tetra-substituted-3-aminopyrrolidine derivative
EP1926372A2 (en) * 2005-08-19 2008-06-04 Cylene Pharmaceuticals, Inc. HUMAN RIBOSOMAL DNA(rDNA) AND RIBOSOMAL RNA (rRNA) NUCLEIC ACIDS AND USES THEREOF
US8580814B2 (en) * 2006-04-03 2013-11-12 Sunesis Pharmaceuticals, Inc. Methods of using (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4- oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of cancer
AU2013219242C1 (en) * 2005-09-02 2016-09-22 Sunesis Pharmaceuticals, Inc. Methods of using (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of cancer
EP1931339B1 (en) * 2005-09-02 2018-05-16 Sunesis Pharmaceuticals, Inc. Methods of using (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of cancer
CA2845095A1 (en) * 2005-09-02 2007-03-08 Sunesis Pharmaceuticals, Inc. Methods of using (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of cancer
CN104873502A (zh) * 2005-09-02 2015-09-02 逊尼希思制药公司 使用(+)-1,4-二氢-7-[(3s,4s)-3-甲氧基-4-(甲氨基)-1-吡咯烷基]-4-氧代-1-(2-噻唑基)-1,8-萘啶-3-羧酸治疗癌症的方法
RU2428983C2 (ru) * 2005-09-02 2011-09-20 Санесис Фармасьютикалз, Инк. Способы применения (+)-1,4-дигидро-7-[(3s,4s)-3-метокси-4-(метиламино)-1-пирролидинил]-4-оксо-1-(2-тиазолил)-1,8-нафтиридин-3-карбоновой кислоты для лечения рака
US7642270B2 (en) 2005-09-14 2010-01-05 Janssen Pharmaceutica N.V. 5-oxo-5,8-dihydro-pyrido-pyrimidine as inhibitors of c-fms kinase
TW200800983A (en) 2005-09-14 2008-01-01 Janssen Pharmaceutica Nv 5-oxo-5,8-dihydro-pyrido-pyrimidines as inhibitors of C-FMS kinase
BRPI0615838A2 (pt) * 2005-09-14 2011-05-31 Janssen Pharmaceutica Nv 5-oxo-5,8-dihidro-pirido-pirimidinas como inibidores de ofc-fms cinase
US8124773B2 (en) 2006-06-12 2012-02-28 Sunesis Pharmaceuticals, Inc. 1,8-naphthyridine compounds for the treatment of cancer
US20100048609A1 (en) * 2006-08-01 2010-02-25 Jacobs Jeffrey W Pharmaceutical dosage forms for (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid
ES2556677T3 (es) * 2006-08-02 2016-01-19 Sunesis Pharmaceuticals, Inc. Utilización combinada de ácido (+)-1,4-dihidro-7-[(3S,4S)-3-metoxi-4-(metilamino)-1-pirrolidinil]-4-oxo-1-(2-tiazolil)-1,8-naftiridin-3-carboxílico y citarabina (Ara-C) para el tratamiento de la leucemia
EP2214662B1 (en) * 2007-10-22 2016-07-13 Sunesis Pharmaceuticals, Inc. (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid in combination with gemcitabine for use in treating cancer
EP2249831A2 (en) * 2007-12-10 2010-11-17 Sunesis Pharmaceuticals, Inc. Methods of using (+)-1,4-dihydro-7-ý(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl¨-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of antecedent hematologic disorders
WO2010078294A1 (en) * 2008-12-31 2010-07-08 Sunesis Pharmaceutical, Inc. Method of preparing (+)-1,4-dihydro-7-[(3s,4s)-3methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid
SG173855A1 (en) 2009-02-27 2011-09-29 Sunesis Pharmaceuticals Inc Methods of using sns-595 for treatment of cancer subjects with reduced brca2 activity
UA110465C2 (en) * 2009-09-04 2016-01-12 Sunesis Pharmaceutecals Inc Stable sns-595 composition
TW201120037A (en) * 2009-10-26 2011-06-16 Sunesis Pharmaceuticals Inc Compounds and methods for treatment of cancer
SI2712358T1 (sl) 2011-05-13 2017-03-31 Array Biopharma, Inc. Spojine pirolidinil sečnine, pirolidinil tiosečnine in pirolidinil gvanidina kot inhibitorji kinaze trka
CN103497186B (zh) * 2013-09-24 2015-02-25 浙江司太立制药股份有限公司 含有烷氧亚氨基取代的萘啶酮羧酸衍生物及其制备方法
US11286255B2 (en) 2017-03-24 2022-03-29 Wakunaga Pharmaceutical Co., Ltd. Pyridone carboxylic acid derivative or salt thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3988463A (en) * 1974-05-06 1976-10-26 Merck & Co., Inc. Method of preventing metastasis of H. Ep. No. 3
US4384001A (en) * 1978-12-21 1983-05-17 Gosalvez Mario Treatment of tumors with thiazolidine-4-carboxylic acid
US4730000A (en) * 1984-04-09 1988-03-08 Abbott Laboratories Quinoline antibacterial compounds
DE3577089D1 (de) * 1984-01-26 1990-05-17 Abbott Lab Antibakterielle chinolinderivate.
NZ210847A (en) * 1984-01-26 1988-02-29 Abbott Lab Naphthyridine and pyridopyrimidine derivatives and pharmaceutical compositions
JPS61152682A (ja) * 1984-12-27 1986-07-11 Dainippon Pharmaceut Co Ltd ピリドンカルボン酸誘導体、そのエステルおよびその塩
JPS61251667A (ja) * 1985-04-30 1986-11-08 Otsuka Pharmaceut Co Ltd ベンゾヘテロ環化合物
PT82752B (pt) * 1985-06-13 1988-12-15 Schering Corp Processo para a preparacao de derivados policiclicos de quinolina, naftiridina e pirazinopiridina
US4851425A (en) * 1985-06-14 1989-07-25 The Upjohn Company Cyclopentapyrazole and tetrahydroindazole compounds and their use as anti-inflammatory and anti-allergic agents
JPS6233176A (ja) * 1985-08-05 1987-02-13 Toyama Chem Co Ltd １，４−ジヒドロ−４−オキソナフチリジン誘導体およびその塩
JP2704428B2 (ja) * 1988-06-15 1998-01-26 富山化学工業株式会社 キノロンカルボン酸誘導体またはその塩
DE3906365A1 (de) * 1988-07-15 1990-01-18 Bayer Ag 7-(1-pyrrolidinyl)-3-chinolon- und -naphthyridoncarbonsaeure-derivate, verfahren sowie substituierte (oxa)diazabicyclooctane und -nonane als zwischenprodukte zu ihrer herstellung, und sie enthaltende antibakterielle mittel und futterzusatzstoffe
JPH06233176A (ja) * 1993-01-29 1994-08-19 Sony Corp ビデオカメラ

Also Published As

Publication number Publication date
WO1995034559A1 (en) 1995-12-21
AU2576795A (en) 1996-01-05
AU679859B2 (en) 1997-07-10
FI965020A0 (fi) 1996-12-13
TW319769B (enExample) 1997-11-11
RO117793B1 (ro) 2002-07-30
US5817669A (en) 1998-10-06
SI0787726T1 (en) 2002-04-30
FI112485B (fi) 2003-12-15
CZ364396A3 (en) 1997-06-11
CA2192824C (en) 2006-11-07
SK157496A3 (en) 1997-08-06
CZ292631B6 (cs) 2003-11-12
BR9508037A (pt) 1997-09-16
SK281341B6 (sk) 2001-02-12
PL317726A1 (en) 1997-04-28
HU220072B (hu) 2001-10-28
NO965305L (no) 1997-02-04
CA2192824A1 (en) 1995-12-21
CN1053668C (zh) 2000-06-21
HU9603455D0 (en) 1997-02-28
FI965020A7 (fi) 1996-12-16
NO965305D0 (no) 1996-12-11
HUT75777A (en) 1997-05-28
ES2163512T3 (es) 2002-02-01
EP0787726B1 (en) 2001-11-28
EP0787726A4 (enExample) 1997-08-06
CN1158614A (zh) 1997-09-03
PT787726E (pt) 2002-04-29
KR100350921B1 (ko) 2002-11-18
PL181867B1 (pl) 2001-09-28
JP3391796B2 (ja) 2003-03-31
EP0787726A1 (en) 1997-08-06
NO307255B1 (no) 2000-03-06
DE69524251T2 (de) 2002-07-11
ATE209645T1 (de) 2001-12-15
HK1000495A1 (en) 2002-07-19
DE69524251D1 (de) 2002-01-10
MX9606331A (es) 1997-03-29
RU2151770C1 (ru) 2000-06-27
NZ287139A (en) 1997-07-27

Similar Documents

Publication Publication Date Title
DK0787726T3 (da) Ny forbindelse, fremgangsmåde til fremstilling deraf og antitumor-middel
NO992549L (no) Sukkerforbindelse, geleringsmiddel og fremgangsmåte for fremstilling derav
UA41872C2 (uk) 2-ціано-1,3-діонові похідні, спосіб їх одержання, гербіцидна композиція, спосіб пригнічення росту бур'янів
ZA88309B (en) 3(2h)pyridazinone,process for its preparation and antagonistic agent against srs-a containing it
GR3003776T3 (enExample)
EP0245902A3 (en) Benzothiazinone derivatives
YU165791A (sh) Postupak za pripremanje derivata 8-hlorohinolona
DK0812838T3 (da) Pyridoncarboxylsyrederivater substitueret med bicyclisk aminogruppe, estere og salte deraf og bicyclisk amin som mellemprodukt
DE3667788D1 (de) Diphenyletherherbizide.
ATE197157T1 (de) Azapeptid-derivate
DE69828087D1 (de) Aminderivate
BR9305092A (pt) Processo para a preparação de derivados de 5-pirazolmercáptan, composto ditiocarbazato de etilideno, processo para a preparação de derivados do mesmo
MY104164A (en) Heterocyclic compounds.
DK0823254T3 (da) Hidtil ukendt anvendelse af pyrazolopyridinforbindelser
EP0827961A4 (en) METHOD FOR PRODUCING BETA-LACTAM COMPOUNDS
DK284080A (da) Fremgangsmaade til fremstilling af clavulansyrederivater